按方案重复肾活检可预测增殖性狼疮肾炎复发及长期结局
结果显示重复活检的高活动性指数与肾复发风险增加相关,高慢性指数与血清肌酐持续升高相关,提示重复肾活检应作为治疗评估的组成部分。
要点
- 重复肾活检高活动性指数与肾复发风险增加独立相关(HR=1.2)。
- 重复肾活检高慢性指数与血清肌酐持续升高相关(HR=1.8)。
- 即使尿蛋白/肌酐比值<1.0 g/g,部分患者仍存在高组织学活动性。
核心结论
- 按方案重复肾活检有助于预测狼疮肾炎复发和长期肾功能损害,应纳入治疗评估。
研究设计与样本
- 评估所有活检的美国国立卫生研究院活动性指数和慢性指数评分。
主要发现
- 重复活检时尿蛋白/肌酐比值与活动性指数呈中度相关(r=0.48;P=0.001)。
- 10例(23.8%)尿蛋白/肌酐比值<1.0 g/g的患者仍存在高组织学活动性(活动性指数>3)。
- 重复活检高活动性指数与肾复发风险增加和/或复发时间缩短相关(HR=1.2,95%CI:1.1,1.3;P=0.007),独立于蛋白尿水平。
- 重复活检高慢性指数与血清肌酐持续升高至基线值≥120%相关(HR=1.8,95%CI:1.1,2.9;P=0.016),中位随访131.5个月。
- 重复活检(而非基线活检)中的急性肾小管间质炎症和间质纤维化/肾小管萎缩也与上述结局相关。
关键数值与推荐
- 重复活检中位时间24.3个月(IQR 21.3-26.2)。
- 肾复发定义为重复活检后复发(n=11)。
- 血清肌酐持续升高定义为≥120%基线值。
- 随访中位时间131.5个月(IQR 73.8-178.2)。
临床怎么用
- 对初发增殖性狼疮肾炎患者,即使临床反应良好,也应考虑按方案重复肾活检以评估组织学活动性和慢性化程度。
- 重复活检的高活动性指数提示复发风险增加,高慢性指数提示长期肾功能损害风险。
局限性
- 单中心数据库来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with LN, clinical and histological responses to treatment have been shown to be discordant. We investigated whether per-protocol repeat kidney biopsies are predictive of LN relapses and long-term renal function impairment. METHODS: Forty-two patients with incident biopsy-proven active proliferative (class III/IV±V) LN from the database of the UCLouvain were included in this retrospective study. Per-protocol repeat biopsies were performed after a median [interquartile range (IQR)] time of 24.3 (21.3-26.2) months. The National Institutes of Health activity index (AI) and chronicity index (CI) scores were assessed in all biopsies. RESULTS: Despite a moderate correlation between urinary protein/creatinine ratios (UPCR) and AI scores at repeat biopsy (r = 0.48; P = 0.001), 10 patients (23.8%) with UPCR < 1.0 g/g still had a high degree of histological activity (AI > 3). High AI scores (continuous) in repeat biopsies were associated with an increased probability and/or shorter time to renal relapse (n = 11) following the repeat biopsy [hazard ratio (HR) = 1.2, 95% CI: 1.1, 1.3; P = 0.007], independently of proteinuria levels. High CI scores (continuous) in repeat biopsies were associated with a sustained increase in serum creatinine levels corresponding to ≥120% of the baseline value (HR = 1.8, 95% CI: 1.1, 2.9; P = 0.016) through a median (IQR) follow-up time of 131.5 (73.8-178.2) months, being also the case for acute tubulointerstitial inflammation and interstitial fibrosis/tubular atrophy in repeat but not baseline biopsies. CONCLUSION: Our results highlight the usefulness of per-protocol repeat biopsies, herein performed after a median time of 24 months from baseline, as an integral part of the treatment evaluation, also in patients showing adequate clinical response.
引用
- Parodis I, Adamichou C, Aydin S, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020. PMID: 32353879. doi:10.1093/rheumatology/keaa129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。